Corebridge price target lowered to $39 from $40 at JPMorgan

JPMorgan lowered the firm’s price target on Corebridge (CRBG) to $39 from $40 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the life insurance space as part of its 2026 outlook. JPMorgan’s outlook for life insurance stocks is positive. The analyst sees a favorable macro backdrop, “healthy” balance sheets, and an expected improvement in operating results. Deterioration in high-grade corporate credit “presents a key risk to a bullish stance on life stocks,” contends the firm.